EGFR and hepatocellular carcinoma: GALNT2 and GALNT4 were found to promote the O-glycan modifications of EGFR to suppress EGF-potentiated HCC pathogenesis [24, 25]; on the contrary, GALNT1 and GALNT10 contributed to HCC malignancy via inducing O-glycosylation-mediated EGFR pathway activation [23, 26].